References
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- Panay N, Fenton A. Bioidentical hormones: what is all the hype about? Climacteric 2010;13:1–3
- Harman SM, Brinton EA, Cedars M, . KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3–12
- Panay N, Fenton A. Alternative regimens for endometrial protection. Where are we now? Climacteric 2011;14:607–8
- Simonn JA. What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric 2012;15(Suppl 1):3–10
- Mueckn AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric 2012;15(Suppl 1):11–17
- Gompeln A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric 2012; 15(Suppl 1):18–25
- Fournier A, Fabre A, Mesrine S, . Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260–8
- Seifert-Klauss V, Schmidmayr M, Hobmaier E, Wimmer T. Progesterone and bone: a closer link than previously realized. Climacteric 2012;15(Suppl 1):26–31